Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump

Celon Pharma said its experimental semaglutide generic, Reduzek, matched Novo Nordisk’s Wegovy/Ozempic in an early-stage bioequivalence study. While results are preliminary, the data supports the company’s positioning as a potential alternative in the obesity market. The news is modestly positive for sentiment, but likely limited near-term impact absent later-stage efficacy/safety confirmation.

Analysis

Celon Pharma said its experimental semaglutide generic, Reduzek, matched Novo Nordisk’s Wegovy/Ozempic in an early-stage bioequivalence study. While results are preliminary, the data supports the company’s positioning as a potential alternative in the obesity market. The news is modestly positive for sentiment, but likely limited near-term impact absent later-stage efficacy/safety confirmation.